Outcome and Disease Progression in NYHA Functional Class I and II Patients With Wild-Type Transthyretin Cardiomyopathy Treated With Tafamidis

JACC Heart Fail. 2025 Aug;13(8):102549. doi: 10.1016/j.jchf.2025.102549. Epub 2025 Jul 3.
No abstract available

Keywords: all-cause death; disease progression; heart failure; prognosis; tafamidis; wild-type transthyretin cardiac amyloidosis.